EVERSPIN TECHNOLOGIES INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that EVERSPIN TECHNOLOGIES INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $49.42M | Mar 15, 2019 |
| FY2018 | Dec 31, 2017 | $35.94M | Mar 15, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.20M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $50.40M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $63.77M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $59.99M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $55.15M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $42.03M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $37.50M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $49.42M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $35.94M | Mar 15, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $10.12M | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | $9.01M | Mar 15, 2018 |
| FY2017 | Jun 30, 2017 | $8.93M | Mar 15, 2018 |
| FY2017 | Mar 31, 2017 | $7.88M | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | $7.06M | Mar 15, 2018 |
| FY2017 | Sep 30, 2016 | $7.16M | Mar 15, 2018 |
| FY2017 | Jun 30, 2016 | $6.66M | Mar 15, 2018 |
| FY2017 | Mar 31, 2016 | $6.21M | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | $6.80M | Mar 29, 2017 |
| FY2016 | Sep 30, 2015 | $7.09M | Mar 29, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.24M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $26.13M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $37.25M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $33.95M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $33.07M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $18.09M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $18.33M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $25.33M | Mar 13, 2020 |
| FY2017 | Dec 31, 2017 | $6.22M | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | $5.26M | Mar 15, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($586.0K) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $781.0K | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $9.05M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $6.13M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $4.34M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($8.51M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($14.67M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($17.75M) | Mar 13, 2020 |
| FY2017 | Dec 31, 2017 | ($4.38M) | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | ($5.45M) | Mar 15, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.51M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($7.09M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $5.89M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $6.23M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $5.04M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($7.56M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($14.41M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($17.32M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($20.21M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($15.52M) | Mar 15, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.09M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $13.69M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $11.78M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $11.11M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $12.63M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $10.90M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $14.18M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $23.64M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $25.44M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $19.23M | Mar 15, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.96M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $7.10M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $13.13M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $9.49M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $9.36M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($2.92M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($8.12M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($14.67M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($18.89M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($18.54M) | Mar 15, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.84M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $3.05M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $1.40M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $2.79M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.03M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $320.0K | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $861.0K | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $1.91M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $3.07M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $1.04M | Mar 15, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $84.61M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $77.79M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $67.30M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $55.33M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $39.38M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $32.53M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $35.37M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $45.05M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $31.44M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $41.47M | Mar 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.69M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $15.20M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $13.38M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $16.67M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $12.14M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $15.12M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $16.88M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $20.12M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $20.55M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $14.60M | Mar 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $68.92M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $62.59M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $53.92M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $38.66M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $27.24M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $17.41M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $18.49M | Mar 9, 2022 |
| FY2020 | Dec 31, 2018 | $24.92M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $10.88M | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | $26.87M | Mar 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($137.46M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($136.87M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($137.65M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($146.70M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($152.83M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($157.17M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($148.66M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($133.99M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($117.54M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($96.44M) | Mar 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.45M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $42.10M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $36.95M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $26.80M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $21.41M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $14.60M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $14.49M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $23.38M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $12.95M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $29.73M | Mar 15, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 9, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 9, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 22.98M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 22.06M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 21.08M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 20.37M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 19.86M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | 19.03M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | 18.08M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | 17.10M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | 12.82M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | 12.50M | Mar 15, 2018 |